FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
The approval covers adjuvant treatment for adults and children aged 2 years and older.
TL;DR
- The FDA approved atezolizumab with fluoropyrimidine and oxaliplatin as adjuvant treatment for Stage III dMMR colon cancer in patients aged 2 years and older. [1,2]
- The agency also approved a subcutaneous atezolizumab-and-hyaluronidase formulation for eligible patients aged 12 years and older who weigh at least 40 kg. [1]
- The decision adds an adjuvant use to the product’s regulatory record; the announcement does not itself establish outcomes for every patient group. [1,2]
On October 8, the FDA approved atezolizumab with fluoropyrimidine and oxaliplatin as adjuvant treatment for adults and pediatric patients aged 2 years and older with Stage III mismatch repair deficient colon cancer. [1] [1]
The FDA also approved atezolizumab with hyaluronidase-tqjs for the same setting in patients aged 12 years and older who weigh at least 40 kg. Fierce Pharma’s regulatory tracker separately reported the approval and identified the ATOMIC trial as its basis. [1,2] [1] [2]
Why it matters
The decision expands the labeled role of an established immunotherapy combination in a defined post-surgical cancer setting. It is a regulatory milestone, not individualized treatment guidance.
Editor's note
Regulatory scope follows the FDA announcement. No treatment recommendation is made.